NMS · Financial Statements

Autolus Therapeutics plc (AUTL) Financial Statements

$1.46 NMS: AUTL

Autolus Therapeutics plc most recently reported annual revenue of $75.0M, a net loss of $288.0M. Revenue grew at an average annual rate of 512.4% over the last 2 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Autolus Therapeutics plc: Revenue rose from $2.0M in 2023 to $75.0M in 2025, a change of +3650.0% over 2 years; net profit was positive in 0 of 5 reported years; operating margin moved from -10583.0% to -359.0%, a shift of +10224.0 percentage points; the most recent year shows a net loss of $288.0M.

Income Statement — 5 Years (USD millions)

Metric20212022202320242025
Revenue——$2.0M$10.0M$75.0M
Operating Expenses——$181.0M$252.0M$346.0M
Operating Profit$-141.0M$-143.0M$-180.0M$-241.0M$-271.0M
Operating Margin0.0%0.0%-10583.0%-2386.0%-359.0%
Other Income$-1.0M$-5.0M$-29.0M$22.0M$-15.0M
Interest$1.0M$9.0M$45.0M$9.0M$37.0M
Depreciation$8.0M$7.0M$7.0M$8.0M$8.0M
Profit Before Tax$-142.0M$-149.0M$-208.0M$-219.0M$-286.0M
Tax$0$0$0$-1.0M$-1.0M
Net Profit$-142.0M$-149.0M$-208.0M$-221.0M$-288.0M
EPS$-1.97$-1.57$-1.20$-0.86$-1.08
Dividend Payout0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

MetricMar '23Jun '23Sep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Mar '26
Revenue————$10.0M$0$0$0$9.0M$21.0M$21.0M$26.0M
Operating Expenses————$49.0M$59.0M$68.0M$76.0M$74.0M$82.0M$93.0M$86.0M
Operating Profit$-39.0M$-44.0M$-43.0M$-53.0M$-39.0M$-59.0M$-68.0M$-76.0M$-65.0M$-61.0M$-72.0M$-60.0M
Operating Margin0.0%0.0%0.0%0.0%-384.0%0.0%0.0%-261600.0%-726.0%-293.0%-338.0%-227.0%
Interest$5.0M$5.0M$5.0M$30.0M$19.0M$10.0M$11.0M$31.0M$10.0M$7.0M$11.0M$11.0M
Profit Before Tax$-40.0M$-46.0M$-46.0M$-77.0M$-53.0M$-58.0M$-82.0M$-26.0M$-68.0M$-48.0M$-79.0M$-71.0M
Tax$0$0$0$0$0$0$0$-6.0M$-3.0M$-1.0M$-1.0M$-1.0M
Net Profit$-40.0M$-46.0M$-46.0M$-77.0M$-53.0M$-58.0M$-82.0M$-28.0M$-70.0M$-48.0M$-79.0M$-72.0M
EPS$-0.23$-0.26$-0.26$-0.45$-0.24$-0.22$-0.31$-0.09$-0.26$-0.18$-0.30$-0.27

Over the 7 years reported for Autolus Therapeutics plc, cash stood at $104.0M in the latest year, shareholders' equity was $1.6B, current assets covered current liabilities 5.97 times.

Balance Sheet — 7 Years (USD millions)

Metric2020202120222022202320242025
Total Assets——$364.0M$364.0M$375.0M$783.0M$589.0M
Current Assets——$309.0M$309.0M$275.0M$661.0M$436.0M
Cash—$310.0M$269.0M$269.0M$240.0M$227.0M$104.0M
Inventory————$0$4.0M$33.0M
Receivables———$0$0$0$24.0M
Fixed Assets——$31.0M$31.0M$35.0M$50.0M$64.0M
Capital Work in Progress$0$0$0$0$0$0$0
Investments———————
Other Assets————$0$12.0M$20.0M
Total Liabilities——$93.0M$93.0M$264.0M$355.0M$411.0M
Current Liabilities——$29.0M$29.0M$45.0M$61.0M$73.0M
Borrowings———————
Other Liabilities——$93.0M$93.0M$264.0M$355.0M$411.0M
Equity——$845.0M$845.0M$1.0B$1.6B$1.6B
Reserves$210.0M$313.0M$313.0M$299.0M$111.0M$427.0M$178.0M

For Autolus Therapeutics plc, operating cash flow was positive in 0 of 5 reported years; free cash flow in the latest year was negative at $303.0M; free cash flow was positive in 0 of 5 years; financing activities used $4.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 5 Years (USD millions)

Metric20212022202320242025
Operating Cash Flow$-118.0M$-112.0M$-146.0M$-206.0M$-284.0M
Investing Cash Flow$-9.0M$-11.0M$-11.0M$-395.0M$158.0M
Financing Cash Flow$284.0M$224.0M$-1.0M$590.0M$-4.0M
Net Cash Flow$157.0M$100.0M$-157.0M$-11.0M$-129.0M
Free Cash Flow$-127.0M$-123.0M$-157.0M$-228.0M$-303.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield—
Quick Ratio5.52
Interest Coverage-7.32
Return 1Y-40.16%
Return 3Y-41.60%
Return 5Y—

Autolus Therapeutics plc (AUTL) financials — frequently asked questions

What is Autolus Therapeutics plc's annual revenue?

Autolus Therapeutics plc (AUTL) reported annual revenue of $75.0M in its most recent fiscal year.

What is Autolus Therapeutics plc's net profit?

Autolus Therapeutics plc (AUTL) reported a net loss of $288.0M in its most recent fiscal year.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
AUTL Overview AUTL Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.